4-[3-Chloro-4-(3,3,3-trifluoro-2-hydroxy-2-methylpropanamido)benzenesulfonyl]-n,n-dimethylbenzamide | 252017-04-2

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[3-Chloro-4-(3,3,3-trifluoro-2-hydroxy-2-methylpropanamido)benzenesulfonyl]-n,n-dimethylbenzamide
• 英文别名: 4-[3-chloro-4-[(3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino]phenyl]sulfonyl-N,N-dimethylbenzamide
• CAS: 252017-04-2
• 化学式: C₁₉H₁₈ClF₃N₂O₅S
• 分子量: 478.9
• InChiKey: DTDZLJHKVNTQGZ-UHFFFAOYSA-N

物化性质

• 沸点：
  683.1±55.0 °C(Predicted)
• 密度：
  1.473±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO 中≥21.85 mg/mL；不溶于水； ≥15.63 mg/mL，乙醇溶液（需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  8

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

生物活性

AZD7545是有效的PDHK抑制剂，对PDHK1和PDHK2的IC50分别为36.8 nM和6.4 nM。在高浓度下不能抑制PDHK4，并能刺激其活性。

目标

Target	Value
PDHK2	6.4 nM
PDHK1	36.8 nM

体外研究

在重组人类PDHK2的存在下，AZD7545增加了PDH的活性，EC50值为5.2 nM。在原代大鼠肝细胞中，AZD7545同样提高了PDH的活性，EC50值为105 nM。AZD7545通过破坏PDHK2与PDC的二氢硫辛酸乙酰转移酶成分（E2）的内部硫辛酰基结构域（L2）的相互作用来抑制PDHK活性。

体内研究

在Wistar大鼠中，AZD7545增加了肝脏和骨骼肌中活性PDH的比例。在肥胖且胰岛素抵抗的Zuker大鼠中，AZD7545能够消除餐后血糖的上升。

文献信息

• MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES
  申请人：Partikula LLC

  公开号：US20180028647A1

  公开（公告）日：2018-02-01

  Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.

  提供了细胞代谢调节剂的组成，通常以靶向细胞糖酵解为目标，最好带有一个靶向基团，直接或间接连接到抑制剂，或连接到纳米颗粒或其他递送载体上，并提供了用于治疗癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的方法。还提供了包括靶向调节剂和药学上可接受的载体的药物组合物。这些药物组合物可以以有效剂量给需要的受试者使用，以减少癌症、增生性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的症状之一或多个，独立使用或在放疗等进一步治疗之前或同时使用。
• Use of compounds for the elevation of pyruvate dehydrogenase activity
  申请人：ZENECA LIMITED

  公开号：US20040009979A1

  公开（公告）日：2004-01-15

  The use of compounds of formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs; in formula (I), Ring C is phenyl or a carbon linked heteroaryl ring substituted as defined within; R 1 is an ortho substituent as defined within; n is 1 or 2; A-B is a linking group as defined within; R 2 and R 3 are as defined within; R 4 is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described. 1

  使用式(I)的化合物及其盐；以及该式(I)化合物的药物可接受的体内可裂解的前药；该化合物或前药的药物可接受的盐；在式(I)中，环C是苯或被定义内取代的碳链杂环；R1是被定义内的邻位取代基；n为1或2；A-B是被定义内的连接基；R2和R3如被定义内；R4为羟基、氢、卤、氨基或甲基；用于制造用于提高温血动物如人类的PDH活性的药物。还描述了制备式(I)化合物的药物组合物、方法和过程。
• Modifications of therapeutic agents for enhanced delivery to target sites
  申请人：Partikula LLC

  公开号：US10478492B2

  公开（公告）日：2019-11-19

  Compositions of a modulator of cell metabolism, typically targeting cellular glycolysis, preferably with a targeting moiety, attached directly or indirectly to the inhibitor, or to a nanoparticle or other delivery vehicle thereof, and methods of use for treating cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases are provided. Pharmaceutical compositions including the targeted modulator and a pharmaceutically acceptable carrier are also provided. The pharmaceutical compositions can be administered to a subject in need thereof in an effective amount to reduce one or symptoms of the cancer, proliferative disorders, neurodegenerative diseases, autoimmune disorders, or inflammatory diseases alone or prior to or in conjunction with a further therapy such as radiotherapy.

  本研究提供了细胞代谢调节剂的组合物，通常以细胞糖酵解为靶标，优选带有靶向分子，直接或间接连接到抑制剂上，或连接到其纳米颗粒或其他递送载体上，以及用于治疗癌症、增殖性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的方法。还提供了包括靶向调节剂和药学上可接受的载体的药物组合物。这些药物组合物可以以有效量施用给有需要的受试者，以减少癌症、增殖性疾病、神经退行性疾病、自身免疫性疾病或炎症性疾病的一种或多种症状，可以单独施用，也可以在放疗等进一步治疗之前或与放疗一起施用。
• Methods of detecting and treating a tumor expressing pT346 PDK1
  申请人：The Wistar Institute of Anatomy and Biology

  公开号：US11208478B2

  公开（公告）日：2021-12-28

  Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.

  公开了表达 pT346 PDK1 的肿瘤（包括表达 pT346 PDK1 的胶质瘤）的治疗方法。
• USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1082110B1

  公开（公告）日：2004-03-24